Novelix is selling 5% of itself to 18 investors for ₹6.84 cr.
The board approved a preferential issue at ₹57 a share, a ₹47 premium to face value. Shareholder approval is needed by July 2026.
— 3 earlier stories on Novelix Pharmaceuticals Ltd. →What's new
- Board approved a preferential allotment of 1.2 million shares to 18 non-promoter investors.
- The issue price is ₹57 per share, a ₹47 premium over face value.
- The raise equals about 4.8% of the company's ₹142 cr market cap.
Why this matters
For a nano-cap with a ₹142 crore market cap, ₹6.84 crore of fresh equity is a material event. It brings cash for the balance sheet but dilutes existing holders by roughly 5%. The company previously flagged a need for capital; this filing delivers the price and the buyers.
What we're watching
- Whether the stock trades near the ₹57 issue price ahead of the EGM.
- The allocation details among the 18 investors once disclosed.
- How the 'general corporate purposes' spending breaks down.
The full read
Novelix is selling about 5% of itself. The board approved a preferential issue of 1.2 million shares to 18 non-promoter investors at ₹57 apiece, a ₹47 premium to face value. That prices the company's equity at ₹6.84 crore of new money. For a firm with a market cap of ₹142 crore, that is 4.8% of its value converted into cash. The terms are clear. The money is for general corporate purposes, though the company has previously linked a capital raise to scaling production. The next step is a shareholder vote on July 1, 2026. The market now has the precise dilution math and the valuation of the new shares to weigh.
Questions answered
- What did Novelix's board approve?
- A preferential allotment of 1.2 million new equity shares to raise ₹6.84 crore. The shares are priced at ₹57 each, a ₹47 premium to face value.
- Who is investing?
- Eighteen non-promoter investors. Their identities are confirmed in the filing, but individual allocation sizes are not disclosed.
- What is the dilution for existing shareholders?
- The ₹6.84 crore raise is worth about 4.8% of the company's ₹142 crore market capitalization, resulting in roughly 5% dilution.
- Is this deal final?
- No. The board has set the terms, but the issue requires shareholder approval at an extraordinary general meeting on July 1, 2026.
- What will the money be used for?
- The filing says 'general corporate purposes.' The analyst rationale notes this follows earlier signals that fresh capital would fund commercial-scale production ambitions.
Story so far
All notes on TRIMURTHI →- 4 Jun 2026 · 10:49 PM IST Novelix is selling 5% of itself to 18 investors for ₹6.84 cr.
- 1d ago Novelix signs German deal to commercialize Astaxanthin production
- 3d ago Novelix Pharmaceuticals preps another equity raise
- 10d ago Novelix calls another board meeting to weigh a new preferential issue